Logo image of CRON

CRONOS GROUP INC (CRON) Stock Fundamental Analysis

USA - NASDAQ:CRON - CA22717L1013 - Common Stock

2.52 USD
+0.04 (+1.61%)
Last: 10/24/2025, 8:17:09 PM
2.5789 USD
+0.06 (+2.34%)
After Hours: 10/24/2025, 8:17:09 PM
Fundamental Rating

5

Taking everything into account, CRON scores 5 out of 10 in our fundamental rating. CRON was compared to 192 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CRON had positive earnings in the past year.
CRON had a positive operating cash flow in the past year.
CRON had negative earnings in 4 of the past 5 years.
CRON had negative operating cash flow in 4 of the past 5 years.
CRON Yearly Net Income VS EBIT VS OCF VS FCFCRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

CRON has a Return On Assets of 1.57%. This is amongst the best in the industry. CRON outperforms 83.85% of its industry peers.
CRON has a better Return On Equity (1.71%) than 81.77% of its industry peers.
Industry RankSector Rank
ROA 1.57%
ROE 1.71%
ROIC N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
CRON Yearly ROA, ROE, ROICCRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

CRON has a better Profit Margin (14.19%) than 89.06% of its industry peers.
CRON's Profit Margin has declined in the last couple of years.
CRON has a Gross Margin (32.74%) which is comparable to the rest of the industry.
Industry RankSector Rank
OM N/A
PM (TTM) 14.19%
GM 32.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
CRON Yearly Profit, Operating, Gross MarginsCRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

More info and screens

8

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRON has been increased compared to 1 year ago.
Compared to 5 years ago, CRON has more shares outstanding
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRON Yearly Shares OutstandingCRON Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CRON Yearly Total Debt VS Total AssetsCRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 7.64 indicates that CRON is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.64, CRON belongs to the best of the industry, outperforming 82.29% of the companies in the same industry.
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.64
ROIC/WACCN/A
WACC7.95%
CRON Yearly LT Debt VS Equity VS FCFCRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 24.65 indicates that CRON has no problem at all paying its short term obligations.
CRON's Current ratio of 24.65 is amongst the best of the industry. CRON outperforms 95.31% of its industry peers.
CRON has a Quick Ratio of 23.53. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
CRON has a Quick ratio of 23.53. This is amongst the best in the industry. CRON outperforms 93.75% of its industry peers.
Industry RankSector Rank
Current Ratio 24.65
Quick Ratio 23.53
CRON Yearly Current Assets VS Current LiabilitesCRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 162.50% over the past year.
The earnings per share for CRON have been decreasing by -50.78% on average. This is quite bad
The Revenue has grown by 28.01% in the past year. This is a very strong growth!
Measured over the past years, CRON shows a very strong growth in Revenue. The Revenue has been growing by 37.71% on average per year.
EPS 1Y (TTM)162.5%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%-400%
Revenue 1Y (TTM)28.01%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%20.51%

3.2 Future

CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.
The Revenue is expected to grow by 7.39% on average over the next years.
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue Next Year12.95%
Revenue Next 2Y21.44%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CRON Yearly Revenue VS EstimatesCRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CRON Yearly EPS VS EstimatesCRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 50.40 indicates a quite expensive valuation of CRON.
Based on the Price/Earnings ratio, CRON is valued a bit cheaper than the industry average as 78.65% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.89. CRON is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 35.29, CRON can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, CRON is valued a bit cheaper than 70.83% of the companies in the same industry.
CRON is valuated expensively when we compare the Price/Forward Earnings ratio to 22.99, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 50.4
Fwd PE 35.29
CRON Price Earnings VS Forward Price EarningsCRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRON Per share dataCRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.5%
EPS Next 3Y3.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRONOS GROUP INC

NASDAQ:CRON (10/24/2025, 8:17:09 PM)

After market: 2.5789 +0.06 (+2.34%)

2.52

+0.04 (+1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06
Inst Owners13.52%
Inst Owner Change1.2%
Ins Owners6.24%
Ins Owner Change0.2%
Market Cap964.88M
Revenue(TTM)130.28M
Net Income(TTM)18.49M
Analysts82.86
Price Target1.77 (-29.76%)
Short Float %1.63%
Short Ratio1.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)-0.21%
Revenue beat(4)1
Avg Revenue beat(4)-1.44%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)9.73%
Revenue beat(8)4
Avg Revenue beat(8)1.96%
Revenue beat(12)4
Avg Revenue beat(12)-3.07%
Revenue beat(16)7
Avg Revenue beat(16)-2.54%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)100%
EPS NY rev (1m)0%
EPS NY rev (3m)65.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.63%
Valuation
Industry RankSector Rank
PE 50.4
Fwd PE 35.29
P/S 7.41
P/FCF N/A
P/OCF 48.18
P/B 0.89
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)0.05
EY1.98%
EPS(NY)0.07
Fwd EY2.83%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.05
OCFY2.08%
SpS0.34
BVpS2.83
TBVpS2.62
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.78
Profitability
Industry RankSector Rank
ROA 1.57%
ROE 1.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14.19%
GM 32.74%
FCFM N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 224.14%
Cap/Sales 22.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.65
Quick Ratio 23.53
Altman-Z 7.64
F-Score7
WACC7.95%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.5%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%-400%
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)28.01%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%20.51%
Revenue Next Year12.95%
Revenue Next 2Y21.44%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
EBIT growth 1Y42.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.35%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y90.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y120.6%
OCF growth 3YN/A
OCF growth 5YN/A

CRONOS GROUP INC / CRON FAQ

What is the fundamental rating for CRON stock?

ChartMill assigns a fundamental rating of 5 / 10 to CRON.


What is the valuation status for CRON stock?

ChartMill assigns a valuation rating of 1 / 10 to CRONOS GROUP INC (CRON). This can be considered as Overvalued.


How profitable is CRONOS GROUP INC (CRON) stock?

CRONOS GROUP INC (CRON) has a profitability rating of 3 / 10.


What is the expected EPS growth for CRONOS GROUP INC (CRON) stock?

The Earnings per Share (EPS) of CRONOS GROUP INC (CRON) is expected to decline by -115.3% in the next year.